Skip to main content

Transgenomic sells Wave System to Genzyme

NEW YORK, April 23 – Transgenomic has sold its Wave genetic analysis system to biotechnology giant Genzyme, the companies said Monday.

Genzyme will use the system in its research on genetic mutations that cause or are associated with hereditary diseases such as lysosomal storage disorders and some cancers. 

"The ongoing challenge for human genome research is to understand the relationship between genetic mutations and diseases such as cancer,” said Transgenomic Chief Executive Officer, Collin D'Silva, in a statement. “The Wave System has been widely recognized as one of the fastest, most sensitive and cost-effective tools for genetic analysis."

The Wave System is designed to identify DNA mutations using micro-bead technology. The product packs micro-beads, each of which has a proprietary surface chemistry that interacts with DNA molecules, into a DNA separation column. The product than uses liquid reagents to separate out the molecules. The analysis is performed using the company’s bioinformatics Wavemaker software

D’Silva said that Transgenomic, of Omaha, Neb., has placed the Wave system in over 500 medical research institutions and biotechnology companies.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.